NASDAQ:PACB - Pacific Biosciences of California Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pacific Biosciences of California Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.28 -0.28 (-7.87 %) (As of 03/30/2020 01:11 AM ET) Add Compare Today's Range$3.17Now: $3.28▼$3.5050-Day Range$2.36MA: $3.69▼$4.8252-Week Range$2.20Now: $3.28▼$7.50Volume1.07 million shsAverage Volume2.83 million shsMarket Capitalization$502.27 millionP/E RatioN/ADividend YieldN/ABeta2.11 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, Africa, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:PACB Previous Symbol CUSIP69404D10 CIK1299130 Webhttp://www.pacb.com/ Phone650-521-8000Debt Debt-to-Equity Ratio0.76 Current Ratio1.65 Quick Ratio1.38Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$90.89 million Price / Sales5.53 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book9.11Profitability EPS (Most Recent Fiscal Year)($0.55) Net Income$-84,130,000.00 Net Margins-92.57% Return on Equity-121.70% Return on Assets-51.76%Miscellaneous Employees401 Outstanding Shares153,130,000Market Cap$502.27 million Next Earnings Date5/1/2020 (Estimated) OptionableOptionable Receive PACB News and Ratings via Email Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PACB Rates by TradingView Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions How has Pacific Biosciences of California's stock been impacted by COVID-19 (Coronavirus)? Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PACB stock has decreased by 4.7% and is now trading at $3.28. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Pacific Biosciences of California? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pacific Biosciences of California. When is Pacific Biosciences of California's next earnings date? Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Friday, May 1st 2020. View our earnings forecast for Pacific Biosciences of California. How were Pacific Biosciences of California's earnings last quarter? Pacific Biosciences of California (NASDAQ:PACB) announced its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.04. The biotechnology company had revenue of $21.92 million for the quarter, compared to analyst estimates of $28.02 million. Pacific Biosciences of California had a negative net margin of 92.57% and a negative return on equity of 121.70%. View Pacific Biosciences of California's earnings history. What price target have analysts set for PACB? 3 equities research analysts have issued twelve-month price targets for Pacific Biosciences of California's stock. Their forecasts range from $5.00 to $8.00. On average, they expect Pacific Biosciences of California's stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 103.3% from the stock's current price. View analysts' price targets for Pacific Biosciences of California. What are Wall Street analysts saying about Pacific Biosciences of California stock? Here are some recent quotes from research analysts about Pacific Biosciences of California stock: 1. According to Zacks Investment Research, "Pacific Biosciences has been gaining ground in the MedTech space on strong Sequel performance. The company’s product revenues also shot up in recent times. Meanwhile, one of Pacific Biosciences’ biggest rival — Illumina — recently announced the termination of the formerly announced $1.20 billion-merger agreement. Per management, Illumina will be paying Pacific Biosciences a termination fee of $98 million. Expansion in gross margin in recent times is also a positive. On the flip side, significant rise in operating expenses remains concerning. The company’s loss per share remained flat year over year. The DNA sequencing market is fraught with competition. The stock has underperformed its industry in a year’s time and is overvalued at the moment." (1/7/2020) 2. Cantor Fitzgerald analysts commented, "We think PACB’s long-read next-generation sequencing platform is the industry standard for deep genomic analysis in human, plant, and animal genomes, as well as RNA. The company has seen mixed revenue performance over the past three years, but we think PACB is getting close to an inflection point, which we think the Street is missing. We see the path to revenue acceleration as multifactorial. These include the launch of its 8 million ZMW SMRT cell, increased penetration of the plant and animal sequencing market, and significant sequencing cost reduction per human genome enabling PACB to become a more mainstream player in human genomics." (5/3/2019) Has Pacific Biosciences of California been receiving favorable news coverage? Press coverage about PACB stock has been trending somewhat negative on Monday, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pacific Biosciences of California earned a news impact score of -1.8 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutPacific Biosciences of California. Are investors shorting Pacific Biosciences of California? Pacific Biosciences of California saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 21,266,400 shares, an increase of 19.1% from the February 27th total of 17,860,000 shares. Based on an average daily volume of 2,755,100 shares, the short-interest ratio is currently 7.7 days. Currently, 15.3% of the shares of the company are sold short. View Pacific Biosciences of California's Current Options Chain. Who are some of Pacific Biosciences of California's key competitors? Some companies that are related to Pacific Biosciences of California include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Charles River Laboratories Intl. (CRL), Bruker (BRKR), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD). What other stocks do shareholders of Pacific Biosciences of California own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Novavax (NVAX), Illumina (ILMN), Crispr Therapeutics (CRSP), Sangamo Therapeutics (SGMO), Gilead Sciences (GILD), FireEye (FEYE), Advanced Micro Devices (AMD), Amarin (AMRN), Micron Technology (MU) and CenterPoint Energy (CNP). Who are Pacific Biosciences of California's key executives? Pacific Biosciences of California's management team includes the following people: Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 70)Ms. Susan K. Barnes, Exec. VP & CFO (Age 65)Mr. James Michael Phillips, Sr. VP of R&D (Age 68)Dr. Stephen Turner, Co-Founder & CTO (Age 51)Dr. Jonas Korlach Ph.D., Chief Scientific Officer What is Pacific Biosciences of California's stock symbol? Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB." Who are Pacific Biosciences of California's major shareholders? Pacific Biosciences of California's stock is owned by many different institutional and retail investors. Top institutional investors include CNH Partners LLC (4.55%), Magnetar Financial LLC (4.52%), Capital International Investors (3.45%), Water Island Capital LLC (3.09%), ArrowMark Colorado Holdings LLC (2.44%) and State Street Corp (2.12%). Company insiders that own Pacific Biosciences of California stock include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View institutional ownership trends for Pacific Biosciences of California. Which major investors are selling Pacific Biosciences of California stock? PACB stock was sold by a variety of institutional investors in the last quarter, including ARP Americas LP, SG Americas Securities LLC, Havens Advisors LLC, Man Group plc, UBS Group AG, Marshall Wace LLP, Gabelli Funds LLC, and Alpine Global Management LLC. Company insiders that have sold Pacific Biosciences of California company stock in the last year include James Michael Phillips, Michael Hunkapiller, and Susan K Barnes. View insider buying and selling activity for Pacific Biosciences of California. Which major investors are buying Pacific Biosciences of California stock? PACB stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Farallon Capital Management LLC, Public Sector Pension Investment Board, ARK Investment Management LLC, Segantii Capital Management Ltd, Aviva PLC, Alliancebernstein L.P., and Schonfeld Strategic Advisors LLC. View insider buying and selling activity for Pacific Biosciences of California. How do I buy shares of Pacific Biosciences of California? Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Pacific Biosciences of California's stock price today? One share of PACB stock can currently be purchased for approximately $3.28. How big of a company is Pacific Biosciences of California? Pacific Biosciences of California has a market capitalization of $502.27 million and generates $90.89 million in revenue each year. The biotechnology company earns $-84,130,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Pacific Biosciences of California employs 401 workers across the globe. View additional information about Pacific Biosciences of California. What is Pacific Biosciences of California's official website? The official website for Pacific Biosciences of California is http://www.pacb.com/. How can I contact Pacific Biosciences of California? Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected] MarketBeat Community Rating for Pacific Biosciences of California (NASDAQ PACB)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 405 (Vote Outperform)Underperform Votes: 330 (Vote Underperform)Total Votes: 735MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe PACB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/30/2020 by MarketBeat.com StaffFeatured Article: Stock Selection - What is cash flow?
